[Comparison of the effect of nitroglycerine and pentaerithritol compositum on exercise time restricted by anginal pain or objective parameters of ischaemia in patients with stable angina].

Abstract

Short acting nitrates are commonly used to prevent the anginal pain. The purpose of the study was to compare antianginal efficacy of Pentaerythritol compositum (20 mg of pentaerythritol tetranitrate and 0.5 mg of nitroglicerine) and 0,5 mg of nitroglycerine. Twenty patients aged 45-75 years with stable angina were enrolled. Antianginal effectiveness was evaluated during treadmill test. Time to ischemic pain and/or electrocardiographic parameters of ischemia were measured. It was found that Pentaerythritol compositum was superior to nitroglycerine in preventing angina with the difference disappearing 60 minutes after drug administration. Both drugs were well tolerated. Achieved results show that Pentaerythritol compositum can be effective as antianginal drug in patients with stable angina.

• Authors: Maciej Siński, Jacek Lewandowski, Piotr Abramczyk, Halina Nowosad, Hanna Grzelak-Szafrańiska
• Journal: Polskie Archiwum Medycyny Wewnetrznej (Pol Arch Med Wewn) Vol. 114 Issue 2 Pg. 755-60 (Aug 2005) Poland
• Vernacular Title: Porównanie wpływu nitrogliceryny i preparatu złozonego pentaerythritol compositum w postaci podjezykowej na czas wystapienia dolegliwości dławicowych i obiektywnych wskaźników niedokrwienia podczas wysiłku fizycznego u chorych ze stabilna choroba niedokrwienna.
• PMID: 16808313 (Publication Type: Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Vasodilator Agents
• Pentaerythritol Tetranitrate
• Nitroglycerin

Topics

• Aged
• Angina Pectoris (complications, drug therapy, physiopathology)
• Chest Pain (drug therapy)
• Double-Blind Method
• Exercise Test (drug effects)
• Female
• Humans
• Male
• Middle Aged
• Myocardial Ischemia (complications, drug therapy)
• Nitroglycerin (therapeutic use)
• Pain (etiology, physiopathology)
• Pentaerythritol Tetranitrate (therapeutic use)
• Treatment Outcome
• Vasodilator Agents (therapeutic use)